Intramuscular Administration of Hydroxyprogesterone Caproate in patients with Endometrial Carcinoma: Pharmacokinetics and effects on adrenal function

References

• Bergsjø P. Progesterone and progestational compounds in the treatment of advanced endometrial carcinoma. Acta Endocrinol 1965; 49: 412–26
   PubMedGoogle Scholar
• Kohorn El. Gestagens and endometrial carcinoma. Gy-necol Oncol 1976; 4: 398–411
   PubMedGoogle Scholar
• Piver M S., Barlow J J., Lurain J R., Blumenson L E. Med-roxyprogesterone acetate vs. hydroxyprogesterone cap-roate in women with metastatic endometrial adenocar-cinoma. Cancer 1980; 45: 268–72
   PubMed Web of Science ®Google Scholar
• Aalders J G., Abeler V, Kolstad P. Recurrent adenocar-cinoma of the endometrium: A clinical and histopatho-logical study of 379 patients. Gynecol Oncol 1984; 17: 85–103
   PubMed Web of Science ®Google Scholar
• Jeppsson S. Background, development and properties of progestogens, with special reference to medroxy-pro-gesterone acetate (MPA). Acta Obstet Gynecol Scand, Suppl. 1981; 101: 7–10
   Google Scholar
• Jeppsson S, Johansson E D., Ljungberg O, et al. Endometrial histology and circulating levels of medroxypro-gesterone acetate (MPA), estradiol, FSH and LH in women with MPA induced amenorrhea compared with women with secondary amenorrhea. Acta Obstet Gynecol Scand 1977; 56: 43–8
   PubMed Web of Science ®Google Scholar
• Sail S, DiSaia P, Morrow P, et al. A comparison of medroxyprogesterone serum concentrations by the oral or intramuscular route in patients with persisting or recurrent endometrial carcinoma. Am J Obstet Gynecol 1979; 135: 647–50
   Google Scholar
• Hesselius I, Johansson E DB. Medroxyprogesterone acetate (MPA) plasma levels after oral and intramuscular administration in a long-term study. Acta Obstet Gynecol Scand, Suppl. 1981; 101: 65–70
   Google Scholar
• Johansson E DB, Messinis I E., Nillius S J. Unopposed endogenous estrogens and the incidence of cancer in female reproductive organs. Acta Obstet Gynecol Scand, Suppl. 1981; 101: 17–20
   Google Scholar
• Vermeulen A. Postmenopausal ovarian function. The endocrine function of the human ovary, V H. James. Academic Press, London 1976; 237–44
   Google Scholar
• Brody S, Carlström K, Lagrelius A, Lunell N O., Rosen-Borg L. Adrenal steroids, bone mineral content and endometrial pathology in postmenopausal women. Acta Obstet Gynecol Scand 1981; 60: 325–6
   Web of Science ®Google Scholar
• Jones J R., DelRosario L, Sorero A A. Adrenal function in patients receiving medroxyprogesterone acetate. Contraception 1974; 10: l–11
   Google Scholar
• Willemse P HB, VanVeelen H, Sleijfer D T., et al. Relation between plasma levels of medroxyprogesterone acetate and suppression of adrenal androgens. J Steroid Biochem, Suppl. 1983; 19: 84
   Google Scholar
• Moe N. Short-term progestogen treatment of endometrial carcinoma. Acta Obstet Gynecol Scand 1972; 51: 55–62
   Web of Science ®Google Scholar
• Opstad P K., Aakvaag A. The effect of sleep deprivation on the plasma levels of hormone during prolonged physical strain and caloric deficiency. Eur J Appl Physiol 1983; 51: 97–107
   PubMed Web of Science ®Google Scholar
• Aakvaag A, Bentdal Ø, Quigstad K, et al. Testosterone and testosterone binding (TeBG) in young men during prolonged stress. Int J Androl 1978; 1: 22–31
   Google Scholar
• Opstad P K., Aakvaag A, Rognum T O. Altered hormonal response to short-term bicycle exercise in young men after prolonged physical strain, caloric deficit and sleep deprivation. Eur J Appl Physiol 1980; 45: 51–62
   Web of Science ®Google Scholar
• Goldhirsch A, Cavalli F, Ganzina F, . Serum level profile of medroxyprogesterone acetate in breast cancer patients treated intramuscularly with two different dose schedules. Current chemotherapy and immunothera-py, P Periti, G G. Grassi, et al. Am Soc Microbiol, Washington 1981; 1474–6, Proceedings of the 12th International Congress of Chemotherapy
   Google Scholar
• Wybran J. Lynestrenol: A progesterone-like agent with immunostimulatory properties. Recent Results Cancer Res 1980; 75: 180–4
   Google Scholar
• Onsrud M. Adjuvant hydroxyprogesterone caproate in stage I endometrial carcinoma: Changes in numbers and reactivities of some blood lymphocyte subpopulations. Gynecol Oncol 1982; 14: 355–64
   Google Scholar
• Brody S, Carström K, von Uexküll A K., et al. Peripheral hormone levels and endometrial condition in postmenopausal women. Acta Obstet Gynecol Scand 1983; 62: 525–9
   Web of Science ®Google Scholar
• Sadoff L, Lusk W. The effect of large doses of medroxyprogesterone acetate (MPA) on urinary estrogen levels and serum levels of cortisol, T4, LH, and testosterone in patients with advanced cancer. Obstet Gynecol 1974; 43: 262–6
   Google Scholar
• Sherman Al, Woolf R B. An endocrine basis for endometrial carcinoma. Am J Obstet Gynecol 1959; 77: 233–42
   PubMed Web of Science ®Google Scholar
• Edgren R A., Hambourger W E., Calhoun D W. Production of adrenal atrophy by 6-methyl-17-acetoxyproges-terone, with remarks to the adrenal effects of other pro-gestational agents. Endocrinology 1959; 65: 505–7
   Google Scholar